Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass

B. Trimarco, G. Lembo, N. DeLuca, B. Ricciardelli, G. Rosiello, M. Volpe, G. Orofino, M. Condorelli

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The antihypertensive efficacy of a new β-blocker, celiprolol, was compared with that of a well established antihypertensive drug, metoprolol. Systemic and forearm haemodynamic effects were investigated using echocardiography and two-dimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive patients completed the double-blind crossover randomized study. Each 6-week active treatment period was both preceded and followed by 2 weeks of placebo treatment such that the total duration of the study was 18 weeks. Despite comparable efficacy in reducing systolic and diastolic blood pressures by approximately 10% of the basal value, the two drugs differed in their systemic and haemodynamic effects. Celiprolol significantly decreased forearm peripheral resistance and total peripheral resistance. Cardiac output remained unchanged and forearm blood flow was increased. Metoprolol reduced cardiac output through a reduction in heart rate, but stroke volume was unaltered. Neither drug significantly modified cardiac performance, as evaluated by left ventricular circumferential fibre shortening and left ventricular ejection fraction. Differences in the systemic and regional haemodynamic effects of the two drugs could account for the different blood pressure response seen in some patients. There was no observable change in left ventricular wall thickness or left ventricular mass. These results confirm previous reports which demonstrate that antihypertensive treatment with β-blockers does not reduce left ventricular mass in patients with a left ventricle of normal size. It is generally accepted, however, that the ability of β-blockers to reverse left ventricular hypertrophy is unrelated to the individual pharmacological characteristics of each agent.

Original languageEnglish
JournalJournal of International Medical Research
Volume16
Issue numberSUPPL. 1
Publication statusPublished - 1988

Fingerprint

Celiprolol
Hemodynamics
Forearm
Vascular Resistance
Antihypertensive Agents
Metoprolol
Blood pressure
Blood Pressure
Cardiac Output
Stroke Volume
Pharmaceutical Preparations
Echocardiography
Rheology
Doppler Echocardiography
Left Ventricular Hypertrophy
Cross-Over Studies
Heart Ventricles
Blood
Therapeutics
Heart Rate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. / Trimarco, B.; Lembo, G.; DeLuca, N.; Ricciardelli, B.; Rosiello, G.; Volpe, M.; Orofino, G.; Condorelli, M.

In: Journal of International Medical Research, Vol. 16, No. SUPPL. 1, 1988.

Research output: Contribution to journalArticle

Trimarco, B, Lembo, G, DeLuca, N, Ricciardelli, B, Rosiello, G, Volpe, M, Orofino, G & Condorelli, M 1988, 'Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass', Journal of International Medical Research, vol. 16, no. SUPPL. 1.
Trimarco, B. ; Lembo, G. ; DeLuca, N. ; Ricciardelli, B. ; Rosiello, G. ; Volpe, M. ; Orofino, G. ; Condorelli, M. / Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass. In: Journal of International Medical Research. 1988 ; Vol. 16, No. SUPPL. 1.
@article{8140717e125b488782c70901d38f93f1,
title = "Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass",
abstract = "The antihypertensive efficacy of a new β-blocker, celiprolol, was compared with that of a well established antihypertensive drug, metoprolol. Systemic and forearm haemodynamic effects were investigated using echocardiography and two-dimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive patients completed the double-blind crossover randomized study. Each 6-week active treatment period was both preceded and followed by 2 weeks of placebo treatment such that the total duration of the study was 18 weeks. Despite comparable efficacy in reducing systolic and diastolic blood pressures by approximately 10{\%} of the basal value, the two drugs differed in their systemic and haemodynamic effects. Celiprolol significantly decreased forearm peripheral resistance and total peripheral resistance. Cardiac output remained unchanged and forearm blood flow was increased. Metoprolol reduced cardiac output through a reduction in heart rate, but stroke volume was unaltered. Neither drug significantly modified cardiac performance, as evaluated by left ventricular circumferential fibre shortening and left ventricular ejection fraction. Differences in the systemic and regional haemodynamic effects of the two drugs could account for the different blood pressure response seen in some patients. There was no observable change in left ventricular wall thickness or left ventricular mass. These results confirm previous reports which demonstrate that antihypertensive treatment with β-blockers does not reduce left ventricular mass in patients with a left ventricle of normal size. It is generally accepted, however, that the ability of β-blockers to reverse left ventricular hypertrophy is unrelated to the individual pharmacological characteristics of each agent.",
author = "B. Trimarco and G. Lembo and N. DeLuca and B. Ricciardelli and G. Rosiello and M. Volpe and G. Orofino and M. Condorelli",
year = "1988",
language = "English",
volume = "16",
journal = "Journal of International Medical Research",
issn = "0300-0605",
publisher = "Field House Publishing LLP",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Long-term reduction of peripheral resistance with celiprolol and effects on left ventricular mass

AU - Trimarco, B.

AU - Lembo, G.

AU - DeLuca, N.

AU - Ricciardelli, B.

AU - Rosiello, G.

AU - Volpe, M.

AU - Orofino, G.

AU - Condorelli, M.

PY - 1988

Y1 - 1988

N2 - The antihypertensive efficacy of a new β-blocker, celiprolol, was compared with that of a well established antihypertensive drug, metoprolol. Systemic and forearm haemodynamic effects were investigated using echocardiography and two-dimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive patients completed the double-blind crossover randomized study. Each 6-week active treatment period was both preceded and followed by 2 weeks of placebo treatment such that the total duration of the study was 18 weeks. Despite comparable efficacy in reducing systolic and diastolic blood pressures by approximately 10% of the basal value, the two drugs differed in their systemic and haemodynamic effects. Celiprolol significantly decreased forearm peripheral resistance and total peripheral resistance. Cardiac output remained unchanged and forearm blood flow was increased. Metoprolol reduced cardiac output through a reduction in heart rate, but stroke volume was unaltered. Neither drug significantly modified cardiac performance, as evaluated by left ventricular circumferential fibre shortening and left ventricular ejection fraction. Differences in the systemic and regional haemodynamic effects of the two drugs could account for the different blood pressure response seen in some patients. There was no observable change in left ventricular wall thickness or left ventricular mass. These results confirm previous reports which demonstrate that antihypertensive treatment with β-blockers does not reduce left ventricular mass in patients with a left ventricle of normal size. It is generally accepted, however, that the ability of β-blockers to reverse left ventricular hypertrophy is unrelated to the individual pharmacological characteristics of each agent.

AB - The antihypertensive efficacy of a new β-blocker, celiprolol, was compared with that of a well established antihypertensive drug, metoprolol. Systemic and forearm haemodynamic effects were investigated using echocardiography and two-dimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive patients completed the double-blind crossover randomized study. Each 6-week active treatment period was both preceded and followed by 2 weeks of placebo treatment such that the total duration of the study was 18 weeks. Despite comparable efficacy in reducing systolic and diastolic blood pressures by approximately 10% of the basal value, the two drugs differed in their systemic and haemodynamic effects. Celiprolol significantly decreased forearm peripheral resistance and total peripheral resistance. Cardiac output remained unchanged and forearm blood flow was increased. Metoprolol reduced cardiac output through a reduction in heart rate, but stroke volume was unaltered. Neither drug significantly modified cardiac performance, as evaluated by left ventricular circumferential fibre shortening and left ventricular ejection fraction. Differences in the systemic and regional haemodynamic effects of the two drugs could account for the different blood pressure response seen in some patients. There was no observable change in left ventricular wall thickness or left ventricular mass. These results confirm previous reports which demonstrate that antihypertensive treatment with β-blockers does not reduce left ventricular mass in patients with a left ventricle of normal size. It is generally accepted, however, that the ability of β-blockers to reverse left ventricular hypertrophy is unrelated to the individual pharmacological characteristics of each agent.

UR - http://www.scopus.com/inward/record.url?scp=0023692766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023692766&partnerID=8YFLogxK

M3 - Article

C2 - 2906018

AN - SCOPUS:0023692766

VL - 16

JO - Journal of International Medical Research

JF - Journal of International Medical Research

SN - 0300-0605

IS - SUPPL. 1

ER -